Ixaka: Funding, Investors & Team (Sep 2026)
Ixaka is a regenerative medicine company and developer of advanced cell-based therapeutics for the treatment of serious diseases that are poorly treated with existing therapies. They are conducting clinical trials with their cellular therapies with the intention of obtaining marketing authorization in Europe, the United States and other markets. Their treatments draw on an exceptional understanding of the fundamental science of cell therapies. Their current cell therapies have been developed by the Andalusian Health Authority (Servicio Andaluz de Salud) and Andalusian Initiative of Advanced Therapies and they aim to work with them to develop further cell therapies to treat other indications with high unmet medical needs.
Ixaka has raised $54.0M across 1 funding round on record, the most recent an undisclosed round of $54.0M announced in Jan 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ixaka Company Profile and Key Stats
Latest funding round on record: Jan 2021.
Ixaka Funding Rounds
Ixaka Founders and Leadership Team
No contact details are on record for this team yet.
Ixaka Funding Compared to Other Biotechnology Startups
Ixaka's latest round of $54.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ixaka in Biotechnology and London
Companies Similar to Ixaka
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Ixaka Funding FAQs
What does Ixaka do?
Ixaka is a regenerative medicine company and developer of advanced cell-based therapeutics for the treatment of serious diseases that are poorly treated with existing therapies. They are conducting clinical trials with their cellular therapies with the intention of obtaining marketing authorization in Europe, the United States and other markets. Their treatments draw on an exceptional understanding of the fundamental science of cell therapies. Their current cell therapies have been developed by the Andalusian Health Authority (Servicio Andaluz de Salud) and Andalusian Initiative of Advanced Therapies and they aim to work with them to develop further cell therapies to treat other indications with high unmet medical needs.
How much funding has Ixaka raised?
Ixaka has raised $54.0M across 1 round on record. The most recent is an undisclosed round of $54.0M announced in Jan 2021.
When did Ixaka last raise funding?
Ixaka's most recent funding round on record is an undisclosed round of $54.0M, announced in Jan 2021.
Who is the CEO of Ixaka?
Joe Dupere is listed as CEO at Ixaka.
Where is Ixaka headquartered?
Ixaka is based in London, England, United Kingdom.
How many employees does Ixaka have?
Ixaka is in the 11-50 employee band.
How does Ixaka's funding compare to other Biotechnology startups?
Ixaka's latest round of $54.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Ixaka Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ixaka is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.